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Novel Functions of Intracellular IL-1ra in Human
Dermal Fibroblasts: Implications in the Pathogenesis
of Fibrosis
Siva Kanangat1, Arnold E. Postlethwaite1,2,3, Gloria C. Higgins2,4,6 and Karen A. Hasty1,2,3,5
Intracellular IL-1 receptor antagonist (icIL-1ra) is reportedly involved in functions independent of blocking IL-1
receptor signaling. Fibroblasts derived from the involved skin of patients with systemic sclerosis (SSc) are
predominantly of the myofibroblast phenotype, with higher levels of icIL-1ra compared to normal skin
fibroblasts. We examined the effect of overexpression of icIL-1ra on the phenotype and function of normal
fibroblasts with respect to the expression of alpha smooth muscle actin (a-SMA), a specific marker for
myofibroblasts, and plasminogen activator inhibitor (PAI), a protein involved in fibrogenesis and expressed at
higher levels in myofibroblasts, and the production of collagenase (matrix metalloproteinase-1 (MMP-1)), the
major enzyme involved in the degradation of native collagen in the skin. Normal human foreskin fibroblasts
overexpressing icIL-1ra showed higher levels of a-SMA and PAI and had lower levels of collagenase and MMP-1
mRNA induced by inflammatory cytokines. By contrast, levels of mRNA for tissue inhibitor of metalloprotein-
ase-1 in the transfected cells were not different from the control cells. Pretreatment of the ic-IL-1ra-transfected
cells with antisense oligonucleotide directed against the mRNA of icIL-1ra restored MMP-1 expression induced
by stimulation with IL-1b. Our data indicate novel functions for icIL-1ra, which might be relevant to the genesis
of fibrotic diseases such as SSc.
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INTRODUCTION
Members of the IL-1 family of cytokines are involved in both
acute and chronic inflammatory responses (Kolb et al., 2001)
with a growing body of evidence indicating a pivotal role of
IL-1 in profibrotic responses. Many human and animal studies
have shown the presence of IL-1 in chronic inflamed tissues
and in tissues undergoing fibrotic responses (Phan and
Kunkel, 1992; Thrall and Scalise, 1995; Johnston et al., 1996).
The three well-known constituents of the IL-1 family are IL-1a,
IL-b, and IL-1 receptor antagonist (IL-1ra). Cultured dermal
fibroblasts from systemic sclerosis (SSc) patients express higher
levels of intracellular IL-1a than fibroblasts from healthy controls
(Kawaguchi, 1994; Kawaguchi et al., 1995). SSc dermal
fibroblasts also express higher levels of an isoform of
intracellular IL-1ra (icIL-1ra) than normal fibroblasts after
stimulation with IL-1b or tumor necrosis factor (TNF)-a (Higgins
et al., 1999a). We have previously shown a linkage between the
expressions of these two proteins (Higgins et al., 1999a).
Normal dermal fibroblasts transfected and overexpressing pre-
IL-1a exhibited four-fold higher levels of icIL-1ra than control
fibroblasts. IL-1a-mediated transcriptional regulation of icIL-1ra
has been reported in keratinocytes (La and Fischer, 2001).
Studies by Dewberry et al. (2000) demonstrated enhanced
expression of icIL-1ra type 1 in human coronary artery and
umbilical vein endothelial cells in response to transforming
growth factor (TGF)-b, lipopolysaccharide, and phorbol myr-
istate acetate (PMA) and postulated a role of icIL-1ra in the
development of artherosclerosis. Together, these findings
suggest involvement of an intracellular form of IL-1ra in
fibroblasts associated with fibrotic lesions.
IL-1ra exists as four isoforms capable of binding to IL-1
receptors (IL-1R) without transducing any signals. One isoform
is secreted (sIL-1-1ra), whereas the other three remain
intracellular (Arend and Guthridge, 2000). They are expressed
in a variety of cells such as epithelial cells (especially
those that line the gastrointestinal tract), keratinocytes,
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some lines of human foreskin fibroblasts (our unpublished
observation), vascular smooth muscles, vascular endothelial
cells, monocytes, and polymorphonuclear leukocytes
(Haskill et al., 1991; Muzio et al., 1995; Bocker et al.,
1998; Malyak et al., 1998a, b). It is evident that the secreted
form functions extracellularly as a competitor of IL-1 for IL-1R
binding and hence acts as an anti-inflammatory agent by
preventing the IL-1–IL-1R interaction. However, functions of
the intracellular isoforms are only beginning to be delineated.
Although the report by Irikura et al. (2002) on the epistatic
inter-relationship between IL-1, IL-1ra, and IL-1R1 concluded
that the only essential function of IL-1ra in both health and
disease is competitive inhibition of IL-1R1, some reports have
shown results independent of IL-1–IL-1R interactions. Watson
et al. (1995) reported intrinsic biologic activity for icIL-1ra.
By overexpressing icIL-1ra in an icIL-1ra-negative cell line,
these authors demonstrated significant reduction of steady-
state levels of IL-1-inducible growth-related oncogene (GRO)
mRNA owing to effects on mRNA stability. Similarly, it has
been reported that expression of icIL-1ra type 1 in human
intestinal epithelial cell line Caco-2 inhibited IL-1-induced
IL-8 expression (Bocker et al., 1998). Another report
demonstrated the decrease of NF-kB activity in icIL-1ra-
expressing cells (Wolf et al., 2001; Garat and Arend, 2003).
Most recently, Banda et al. (2005) reported that icIL-1ra type
1 binds to the third component of the COP9 signalosome and
thereby inhibits IL-1-induced cytokine production in keratino-
cytes, again supporting icIL-1ra action independent of IL-1–
IL-1R interaction.
In this study, to further understand the role of icIL-1ra in
the genesis of fibrotic lesions, we overexpressed icIL-1ra type
1 in normal foreskin fibroblasts. Infant fibroblasts were used
to avoid the problem of senescence resulting from repeated
passages during stable transfection. We examined the
phenotype of fibroblasts overexpressing icIL-1ra with respect
to the expression of alpha-smooth muscle actin (a-SMA), a
specific marker of myofibroblasts prevalent in fibrotic lesions
(Tomasek et al., 2002), as well as the expression of
plasminogen activator inhibitor (PAI), reported to be elevated
in myofibroblasts (Higgins et al., 1999b; Offersen et al.,
2003). We also examined the expression levels of matrix
metalloproteinase-1 (MMP-1), tissue inhibitor of metallo-
proteinase-1 (TIMP-1), and collagen type I in infant foreskin
fibroblasts overexpressing icIL-1ra. Our current data support
the idea that icIL-1ra type 1 contributes to the development of
the myofibroblast-like phenotype with enhanced expression
of a-SMA and PAI and also downregulates the expression of
collagenase in response to inflammatory cytokines. The fact
that icIL-1ra is able to inhibit TNF-induced MMP-1 expres-
sion shows that the actions of icIL-1ra are independent of
the IL-1–IL-1R interactions. Collectively, our data indicate
possible important novel roles for icIL-ra.
RESULTS
Expression of icIL-1ra in transfected fibroblasts
Levels of icIL-1ra type 1 mRNA and icIL-1ra protein were
assessed in human fibroblasts transfected with PLXSN-icIL-
1ra (HF-icIL-1ra) and in human fibroblasts transfected with
PLXSN plasmid alone (HF-Vector). Abundant levels of
icIL-1ra type 1 mRNA levels were constitutively expres
sed in HF-icIL-1ra, whereas HF-Vector did not constitu-
tively express detectable levels of icIL-1ra type 1 mRNA
(Figure 1a). However, upon stimulation with human recom-
binant (hr)IL-1b or hrTNF-a, the HF-Vector did express low
levels of icIL-1ra type 1 mRNA (Figure 1a). HF-icIL-1ra
expressed high levels of icIL-1ra protein compared to HF-
Vector (Figure 1b). The culture medium of HF-icIL-1ra was
tested for the presence of secreted IL-1ra and our results
presented in Table 1 show that the culture supernatant had
very low levels (o30 pg/ml) of IL-1ra compared to the ng/ml
levels present in the cell lysates of icIL-1ra-transfected
fibroblasts.
Phenotypic features of dermal fibroblasts overexpressing
icIL-1ra
Myofibroblasts represent a major cell population in various
fibrotic lesions including the involved skin of patients with
scleroderma. We have previously observed enhanced
expression of icIL-1ra in fibroblasts obtained from the
involved skin of patients with scleroderma after IL-1b or
TNF-a stimulation. It was of interest to determine whether
normal fibroblasts overexpressing icIL-1ra would have
features of myofibroblasts. Therefore, we examined the
morphology and a-SMA (a specific marker of myofibro-
blasts) in HF-Vector and HF-icIL-1ra. For these studies,
HF-Vector and HF-icIL-1ra were maintained in culture
with complete Dulbecco’s modified minimal essential
medium (DMEM) for 6 weeks with medium changes every
5th day. HF-Vector retained a spindle-shaped morphology
(Figure 2a) with little staining for a-SMA (Figure 2c). In
contrast, HF-icIL-1ra assumed a myofibroblast-like appear-
ance (Figure 2b) and stained positive for a-SMA (Figure 2d).
Human fibroblasts passed in TGF-b showed myofibroblast
morphology (Figure 2e) and more intense staining for
a-SMA (Figure 2f).
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Figure 1. Overexpression of icIL-1ra in HF-icIL-1ra. (a) Equal number of cells
(HF-icIL-1ra and HF-Vector) were stimulated with 0 and 1.0 ng of hrIL-1b or
10 ng/ml of hrTNF-a. After 24 hours, total RNA was extracted and mRNA
levels of icIL-1ra and GAPDH were estimated by real-time RT-PCR. Ratios of
icIL-1ra type 1 to GAPDH messages are plotted in the graph. (b) Equal
numbers of HF-icIL-1ra and HF-Vector maintained in complete DMEM for
48 hours were harvested and lysed. The clarified cell lysates were tested for
icIL-1ra type 1 by ELISA. The error bars indicate mean7SD of three separate
experiments on the same batch of stably transfected fibroblasts.
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Real-time RT-PCR analysis of constitutive mRNA
expression of a-SMA showed significantly enhanced expres-
sion in HF-icIL-1ra compared to HF-Vector (P¼0.002)
(Figure 3).
Higgins et al. (1999b) have reported that differential
regulation of PAI-1 gene expression in human fibroblasts
predisposed to a fibrotic phenotype. To determine the
possible association between icIL-1ra and expression of PAI
mRNA, HF- icIL-1ra and HF-Vector were examined by real-
time RT-PCR. HF-icIL-1ra had increased constitutive levels
(P¼0.002) of PAI mRNA compared to HF-Vector (Figure 3).
Basal expression of MMP-1 mRNA in icIL-1ra type 1 in
HF-Vector and HF-icIL-1ra
We examined the basal and inducible levels of MMP-1 in
HF-icIL-1ra and HF-Vector. The basal levels of MMP-1
mRNA were remarkably low in HF-icIL-1ra cells compared
to HF-Vector (Figure 4).
Expression of MMP-1 in HF-icIL-1ra type 1-transfected
fibroblasts stimulated with IL-1b, TNF-a, or PMA
To determine the impact of overexpression of icIL-1ra type 1
on induced MMP-1 expression, HF-icIL-1ra or HF-Vector
fibroblasts were stimulated with hrIL-1b and hrTNF-a. The
MMP-1 mRNA levels were analyzed by real-time RT-PCR.
HF-icIL-1ra exhibited a significant decrease in MMP-1 mRNA
levels for both basal and stimulated conditions compared to
HF-Vector (Figure 5). The effect of another potent stimulant
for MMP-1 expression, namely PMA (10 ng/ml), was also
examined in cultures of HF-icIL-1ra and HF-Vector. The
results from two separate experiments showed up to 50%
reduction in MMP-1 mRNA levels in HF-icIL-1ra after PMA
stimulation compared to HF-Vector (data not shown).
In addition to measuring MMP-1 mRNA levels, MMP-1
protein was also measured. Cultures of HF-Vector and
HF-icIL-1ra fibroblasts were collected after 48 hours of
stimulation with 1 ng/ml of hrIL-1b or 5 ng/ml hrTNF-a.
MMP-1 protein levels in culture supernatants were deter-
mined by ELISA. Results from two separate experiments
presented in Figure 6 show significantly reduced levels of
collagenase in HF-icIL-1ra compared to HF-Vector. The
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Figure 3. Enhanced levels of a-SMA and PAI mRNA in HF- icIL-1ra.
HF-icIL-1ra and HF-Vector were maintained in complete DMEM for 6 weeks
with medium changes every 5 days. Cells were harvested and total cellular
RNA was extracted and reverse transcribed. The cDNA thus obtained was
amplified by real-time PCR and quantified by SYBR Green using a-SMA
primers and PAI primers (Table 4). The values are expressed as ratios of Ct
values of a-SMA to those of the housekeeping gene GAPDH. The values
indicate mean7SD of three independent experiments performed on the same
batch of stably transfected fibroblasts.
Table 1. Levels of IL-1ra protein in cell lysates and
culture supernatants of human foreskin fibroblasts
transfected with icIL-1ra-encoding plasmids and in
control fibroblasts
IL-1ra protein
In culture supernatants
(pg/ml)
In cell lysates
(ng/ml)
Samples Exp. 1 Exp. 2 Exp. 1 Exp. 2
HFF-Vector ND ND 2.2 3.2
HFF-icIL-1ra 12 16 11.5 12.6
HFF-Vector-TNF 8 10 4.7 6.8
HFF-icIL-1ra-TNF 25 28 19.3 20.4
HFF-Vector-IL-1 6 7 3.9 3.5
HFF-icIL-1ra-IL-1 20 26 15.5 16.9
Human fibroblasts transfected with plasmid encoding icIL-1ra (HF-icIL-
1ra) and empty vector (HF-Vector) were maintained in DMEM containing
5% FBS. Seventy-two hours after transfection and geneticin selection,
culture supernatants were collected and cell lysates were prepared as
described in Materials and methods. The levels of IL-1ra were estimated
by ELISA using R&D Systems reagents.
a c
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Figure 2. Myofibroblast morphology of HF-icIL-1ra. (a) HF-Vector with
normal spindle-shaped fibroblast morphology after culturing in complete
DMEM for 6 weeks with medium changes every 5 days. (b) HF-icIL-1ra with
myofibroblast-like morphology. (c, d) Cells were fixed and permeabilized
(Cytofix/Cytoperm) and were subjected to immunoperoxidase staining with
mouse anti-human a-SMA (Sigma) clone 1A 4 monoclonal antibody followed
by color reaction developed by a streptavidin–horseradish peroxidase system
as described. (c) HF-Vector with little a-SMA staining. (d) HF-icIL-1ra with
a-SMA staining. (e) HFF-TGF-passed cells with myofibroblast-like
morphology. (f) HFF-TGF with intense staining for a-SMA.
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results show that human fibroblasts overexpressing icIL-1ra
type 1 are refractory to MMP-1 upregulation when exposed to
potent stimulators such as IL-1b, TNF-a, or PMA.
Two other human fibroblast cell lines transfected with
plasmid encoding icIL-1ra also had similar reduced response
to collagenase expression upon treatment with TNF-a. The
data are depicted in Table 2.
Expression of MMP-1 in fibroblasts treated with rhIL-1ra
stimulated prior to stimulation with TNF-a
As we detected low levels of secreted form of IL-1ra in icIL-
1ra-transfected fibroblasts, we decided to determine if
extracellular presence of IL-1ra could mimic the effects of
icIL-1ra on collagenase expression. Fibroblasts were treated
with 0, 25 pg/ml, 1 ng/ml, 10 ng/ml, 15 ng/ml, and 50 ng/ml
rhIL-1ra prior to TNF-a exposure. The results shown in
Table 3 indicate that presence of rhIL-1ra even up to a
concentration of 1.0 ng/ml did not have any significant effect
on collagenase expression as determined by ELISA.
Expression of TIMP-1 mRNAs in HF- icIL-1ra or HF-Vector after
stimulation with TNF-a
As we observed a substantial reduction in basal and IL-1/TNF/
PMA-inducible MMP-1 expression in icIL-1ra-transfected
fibroblasts, we wanted to see if the TIMP-1 expression was
also affected by icIL-1ra. Interestingly, the mRNA levels
of TIMP-1 were not different between TNF-a-stimulated
HF-icIL-1ra and HF-Vector (Figure 7).
Specificity of icIL-1ra type 1 action on MMP-1 expression
To further study the direct relationship between icIL-1ra type
1 and MMP-1 expression, an antisense oligonucleotide for
1 2 1 2 1 2
200 bp DNA ladder GAPDH iclL-1ra MMP-1
2: HF-iclL-1ra1: HF-Vector
Figure 4. Reduced mRNA in HF-icIL-1ra. HF-icIL-1ra and HF-Vector were
maintained in complete DMEM for 6 weeks with medium changes every 5
days. Cells were harvested in Tri-Reagent and total cellular RNA was
extracted. One microgram of total RNA was reverse transcribed in a 20 ml
reverse transcription reaction mixture and 5.0ml of the cDNA was amplified
by 28 cycles of PCR using primers specific for GAPDH and MMP-1. The PCR
products were analyzed on a 2% agarose gel, stained with ethidium bromide,
and photographed.
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Figure 5. Reduced expression of IL-1- and TNF-induced MMP- 1mRNA in
HF-icIL-1ra. HF-icIL-1ra and HF-Vector were stimulated with 1.0 ng/ml
IL-1b or10 ng/ml TNF-a for 12–16 hours. MMP-1 and GAPDH message levels
were estimated using real-time RT-PCR. Three separate experiments were
performed on the same batch of stably transfected fibroblasts. The results are
represented as the reciprocal of the ratios of the Ct values of MMP-1 to those
of GAPDH (the housekeeping gene).
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Figure 6. Reduced levels of MMP-1 protein in HF-icIL-1ra type 1. HF-icIL-
1ra and HF-Vector were cultured for 48 hours with hrIL-1b (1.0 ng/ml) or
hrTNF-a (5 ng/ml) and MMP-1 protein secreted into the culture medium was
measured by ELISA.
Table 2. Reduced collagenase (MMP-1) production in
human foreskin fibroblasts derived from two different
individuals and expressing icIL-1ra
Collagenase (ng/ml)
HFF-414 HFF-419
Samples Exp. 1 Exp. 2 Exp. 1 Exp. 2
HFF-Vector 134 129 152 160
HFF-Vector-TNF 1,625 1,605 1,768 2,363
HFF-icIL-1ra 88 60 78.2 —
HFF-icIL-1ra-TNF 233 213 173 —
Two different lines of human foreskin fibroblasts (HFF-414 and HFF-419)
were transfected with plasmids encoding icIL-1ra (HFF-icIL-1ra) or empty
vector (HFF-Vector). Seventy-two hours after selection with geneticin, the
fibroblasts were exposed to TNF or PBS. Forty-eight hours after TNF-a
treatment, the supernatants were collected and the levels of collagenase
were estimated by ELISA as described in Materials and methods.
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icIL-1ra type 1 mRNA was designed to specifically inhibit the
translation of icIL-1ra type 1 into the corresponding protein.
HF-icIL-1ra fibroblasts stimulated with 1.0 ng/ml IL-1b were
treated with varying concentrations of antisense oligonucleo-
tide directed against icIL-1ra type 1 mRNA. An oligonucleo-
tide with a scrambled sequence was used for the control.
Oligonucleotides were mixed with LipofectAMINE reagent to
enhance cellular uptake. Results presented in Figure 8a (gel)
and Figure 8b (bar graph) show that HF-icIL-1ra treated with
200 mM antisense icIL-1ra type 1 oligonucleotide expressed
significantly higher levels of MMP-1 mRNA compared to the
controls (ie HF-icIL-1ra treated with phosphate-buffered
saline (PBS), with empty liposome, and the oligonucleotide
with the scrambled sequence). The results indicate a direct
association between increased icIL-1ra type 1 and decreased
MMP-1 expression in fibroblasts stimulated by agents, such as
IL-1b, TNF-a, and PMA, that normally upregulate MMP-1.
DISCUSSION
In this study, we present data that attribute to the involvement
of icIL-1ra in fibroblasts in some novel functions relating to
enhanced a-SMA expression and PAI expression, and its
ability to impart resistance to TNF-a-, IL-1-, and PMA-
induced MMP-1 expression. Together, these data indicate the
role of icIL-1ra in the genesis of fibrosis following an
inflammatory response. Our current data are in line with
the previous reports on the cardinal involvement of members
of the IL-1 family in inflammation-associated fibrotic lesions
(Kotecha et al., 1996; Sime and Gauldie, 1996; Mikuniya
et al., 1997, 2000; Marshall et al., 1998; Ziegenhagen et al.,
1998; Whyte et al., 2000; Kolb et al., 2001).
The observed ability of icIL-1ra to inhibit the TNF-a-
induced expression of MMP-1 is evidence toward ascribing
an IL-1R-independent icIL-1ra action. Similar IL-1R-indepen-
dent functions of icIL-1ra have been reported earlier (Watson
et al., 1995; Wolf et al., 2001; Banda et al., 2005). icIL-1ra-
transfected fibroblasts secrete picogram quantities of IL-1ra
into the medium. However, adding recombinant IL-1ra up to
a concentration of 10.0 ng/ml did not have any significant
effect on TNF-a-induced collagenase expression. We there-
fore believe that the effects observed in our present study are
unique to the intracellular form of IL-1ra. Understanding of
the mechanisms by which icIL-1ra type 1 affects MMP-1
expression is only rudimentary and speculative at this junc-
ture. Regulation of MMP-1 expression is complex and may
involve interventions at transcription, post-transcriptional
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Figure 7. Normal expression of TIMP-1 mRNA in fibroblasts overexpressing
icIL-1ra. HF-icIL-1ra type 1 HF-icIL-1ra and HF-Vector were stimulated with
0 or 10 ng/ml TNF-a for 12–16 hours. Total cellular RNA was extracted and
TIMP-1 and GAPDH message levels were estimated using SYBR Green real-
time RT-PCR. The values are expressed as the reciprocal ratios of Ct values of
TIMP-1 mRNA and collagen type I mRNA to those of the housekeeping gene
GAPDH. The values indicate mean7SD of three independent experiments
performed on the same batch of stably transfected fibroblasts.
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Figure 8. Transfection of HF-icIL-1ra with antisense oligonucleotide
directed toward icIL-1ra restores IL-1-induced MMP-1 mRNA expression.
Phosphorothioate-derivatized antisense oligodeoxynucleotide complimentary
to 6 to þ12 of the natural icIL-1ra was synthesized and oligonucleotide
with a scrambled sequence was prepared by a similar method as a control.
HF- icIL-1ra stimulated with 1.0 ng/ml IL-1b was transfected with 300 mM of
antisense icIL-1ra type 1 oligonucleotide (24 hours prior to stimulation with
1.0 ng/ml of IL-1b) using LipofectAMINE. PBS and LipofectAMINE alone
served as additional controls. The cells were harvested 12–18 hours after
stimulation for RNA extraction. Total RNA was reverse transcribed and MMP-1
mRNA was estimated by real-time RT-PCR. The values indicate mean7SD
of three independent experiments performed on the same batch of transfected
geneticin-selected fibroblasts (PBS: PBS alone; LIPO: LipofectAMINE alone;
ANTIS-LIP: antisense icIL-1ra oligonucleotideþ LipofectAMINE; SCRAM-LIP:
scrambled oligonucleotideþ LipofectAMINE).
Table 3. TNF-induced collagenase (MMP-1) produc-
tion in human foreskin fibroblasts exposed to varying
concentrations of human recombinant IL-1ra
MMP-1/collagenase
Samples
MMP-1 mRNA
(relative units)
Collagenase
(ng/ml)
HFF+TNF 2.5270.3 1,202
HFF+25 pg/ml rhIL-1ra+TNF 2.5970.3 1,069
HFF+1 ng/ml rhIL-1ra+TNF 2.7370.5 1,574
HFF+10 ng/ml rhIL-1ra+TNF 2.6370.4 880
HFF+15 ng/ml rhIL-1ra+TNF 2.7770.6 823
HFF+50 ng/ml rhIL-1ra+TNF 2.4270.5 901
Human foreskin fibroblasts maintained in DMEM containing 5% FBS were
exposed to 0, 25 pg/ml, 1 ng/ml, 10 ng/ml, and 50 ng/ml of rhIL-1ra (R&D
Systems). Two hours later, TNF-a was added to a concentration of 5 ng/ml.
The fibroblasts from one set of cultures were harvested after 24 h of TNF-a
treatment and total RNA was isolated. The mRNA levels of MMP-1 were
determined by real-time RT-PCR (Materials and methods). One set of the
culture supernatants was collected 48 h later and the collagenase levels
were detected by ELISA as described in Materials and methods.
760 Journal of Investigative Dermatology (2006), Volume 126
S Kanangat et al.
Novel Effects of icIL-1ra on Human Fibroblasts
processing of mRNA, and cellular translocation (Vincenti
et al., 1996; Cook et al., 2003). Inflammatory cytokines such
as IL-1b and TNF-a used in the current study trigger the
ceramide signaling pathways (Spiegel et al., 1996). Three
distinctive mitogen-activated protein kinase pathways, that is,
extracellular signal-regulated kinase 1/2, stress-activated
protein kinase/c-Jun N-terminal kinase, and p38, are involved
in the ceramide-dependent expression of MMP-1 (Reunanen
et al., 1998). Also, the activator protein-1 (AP-1) pathway is
involved in MMP-1 expression. The effect of PMA on MMP-1
stimulation is mediated via the formation of AP-1 complexes
and their interaction with two AP-1 sites (referred to as
phorbol ester responsive element (TRE)) in the MMP-1
promoter (Angel et al., 1987; Schonthal et al., 1988).
Involvement of AP-1 components c-fos and c-jun in IL-1-
mediated induction of MMP-1 in gingival fibroblasts has been
reported by Hamid et al. (2000). It is possible that icIL-1ra has
the capability to decrease the expression of AP-1 components
or their activity. It is pertinent to note here that icIL-1ra has
been shown to decrease the activity of NF-kB in intestinal
epithelial cells (Garat and Arend, 2003). Also, icIL-1ra-
mediated reduction in stability and/or degradation of MMP-1
mRNA cannot be ruled out as we measured only steady-state
levels of MMP-1 mRNA. A recent study by Reunanen et al.
(2002) has shown enhancement of MMP-1 and MMP-3
mRNA stabilization by activated p38 a-mitogen-activated
protein kinase. Our preliminary microarray data on icIL-1ra-
overexpressing fibroblasts have shown reduced levels of p38
mitogen-activated protein kinase mRNA expression (data not
shown). The ability of icIL-1ra to reduce mRNA stability of
induced message has also been reported by Watson et al.
(1995). These authors expressed icIL-1ra in an icIL-1ra-
negative cell line using a retroviral expression system and
measured the half-life of GRO mRNA upon exposure to
IL-1b. The half-life of GRO mRNA was reduced by more
than half in the icIL-1ra-expressing cell line compared to
the control cell line.
Although there are several potent inducers of MMP-1,
there are only a few effective downregulators of MMP-1
expression, and the regulation appears to be cell dependent.
IFN-g downregulates MMP-1 in fibroblasts and macrophages
(Shapiro et al., 1990; Varga et al., 1995) but upregulates
MMP-1 in keratinocytes (Tamai et al., 1990). The cytokine
TGF-b has long been regarded as a key player in fibrotic
processes including renal fibrosis, pulmonary fibrosis, and
SSc (Leask and Abraham, 2004). It is a potent inhibitor of
MMP-1 expression in fibroblasts (White et al., 2000);
however, it enhances the expression of MMP-1 in epithelial
cells (Strissel et al., 1995). The inhibitory effect of TGF-b has
been reported to be mediated through a TGF-b inhibitory
element present at 249 in the rabbit MMP-1 promoter, and
is conserved at 246 in the human gene (Strissel et al., 1995).
The TGF-b inhibitory element functions as a constitutive
repressor as well as an antagonist of transcriptional induction
by phorbol esters. PMA circumvents specific receptor
activation by binding and activating protein kinase C and
increasing AP-1 complexes and their interaction with two
AP-1 sites (referred to as phorbol ester response element) in
the MMP-1 promoter (Brose and Rosenmund, 2002). As
TIMP-1 is a specific inhibitor of MMP-1, we also examined
the mRNA levels of TIMP-1 in HF-icIL-1ra and HF-Vector.
We did not observe any notable differences in TIMP-1 mRNA
expression between HF-icIL-1ra and HF-Vector, thereby
ruling out the possibilities of TIMP-mediated inhibition of
MMP-1 in HF-icIL-1ra.
The observation that overexpression in normal fibroblasts
of icIL-1ra type 1 induces a myofibroblast phenotype is novel
and is of potential importance to tissue repair and fibrosis.
Myofibroblasts are abundant in granulation tissue of healing
wounds where they are responsible for wound contraction
(Schmitt-Graff et al., 1994). Myofibroblasts are particularly
increased in organs undergoing fibrosis such as lung, kidney,
liver, bone marrow, and eye (Schmitt-Graff et al., 1994). They
comprise a major portion of fibroblasts in dermal lesions of
patients with SSc (490% patients in 50% of the patients
studied; Kirk et al., 1995). In culture, a-SMA-positive
fibroblasts can be grown from cloned a-SMA-negative
fibroblasts (Schmitt-Graff et al., 1994). Several cytokines
and growth factors have been shown to modulate a-SMA
expression in fibroblast cultures. TGF-b increases a-SMA
expression, whereas platelet-derived growth factor, basic
fibroblast growth factor, and IFN-g decrease a-SMA expres-
sion (Schmitt-Graff et al., 1994). Myofibroblasts are also
known to express high levels of PAI, a key player in the
genesis of fibrosis. Reduction in fibrotic tissue formation in
mice genetically deficient in PAI-1 has been reported by
Chuang-Tsai et al. (2003). Ames et al. (1997), in a report on
coagulation/fibrinolysis balance in SSc, showed significantly
elevated levels of PAI in the plasma of patients with the
disease. The overexpression of icIL-1ra type 1 induced a
myofibroblast phenotype with characteristic morphology and
enhanced expression of a-SMA and PAI. The mechanisms of
icIL-1ra-mediated enhancement of a-SMA and PAI expression
and myofibroblast morphology in normal fibroblasts are not
clear at this time. It is possible that icIL-1ra may have altered
actions owing to its retention of the seven additional
N-terminal amino acids, which might confer an intracellular
agonist’s role as speculated by Haskill et al. (1991). Further
studies at the cellular and molecular levels are necessary to
understand the mechanisms involved in icIL-1ra-mediated
upregulation of a-SMA and myofibroblast differentiation.
In conclusion, we have presented evidence for novel
functions of IL-1ra type 1 that could have a potential role in
delineating the molecular events associated with regulation
of collagenase expression and fibroblast–myofibroblast differ-
entiation, both of which are believed to be key events in
normal tissue repair and in the genesis of fibrosis. Our
findings that relate elevated icIL-1ra in fibroblasts to a
reduced responsiveness of the MMP-1 pathway seem to be
appropriate for the myofibroblast phenotype that is normally
committed to matrix deposition.
MATERIALS AND METHODS
All the experiments described in this report were conducted upon
approval of the institutional review board of the University of
Tennessee Health Science Center Memphis, TN, based on the formal
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guarantee (Federal Wide Assurance) provided to the Department of
Health and Human Services and in compliance with the institutional
biosafety committee.
Cloning of icIL-1ra
The icIL-1ra type 1 cDNA insert was prepared as follows: poly(A)þ
RNA obtained from THP-1 monocytic cells (ATCC, Manassas, VA)
stimulated with 1mg/ml lipopolysaccharide and 100 ng/ml PMA was
reverse transcribed using oligo(dT)18 primers and random hexamers.
The cDNA thus obtained was subjected to PCR using 50 and 30
primers corresponding to the coding sequence of icIL-1ra type 1
sequence as reported by Haskill et al. (1991). Desired restriction
enzyme sites were incorporated into the terminals of each primer for
cloning. Correct sequence of the cloned icIL-1ra type 1 was verified
by automated dye terminator cycle sequencing (ABI Prism Kit, Perkin
Elmer, Foster City, CA) at the University of Tennessee Molecular
Resources Center. The sequence of the cloned icIL-1ra corresponds
to the isoform designated as icIL-1ra type 1. The cDNA for icIL-1ra
type 1 was then cloned into an expression plasmid (pLXSN) carrying
a neomycin resistance gene. The icIL-1ra type 1 cDNA was placed
under the control of an simian virus 40 promoter (pLXSN icIL-1ra).
Unmodified plasmid carrying the neomycin resistance gene served
as control (HF-Vector). Plasmids (pLXSN icIL-1ra type 1 and pLXSN-
Vector) were amplified in E. coli HB101/JM109 and purified using
a commercially available plasmid purification kit (Promega,
Madison, WI).
Human dermal fibroblast cultures
Dermal fibroblasts were obtained from infant foreskins by conven-
tional explant culture techniques and grown in DMEM containing
HEPES buffer, non-essential amino acids, sodium pyruvate, 100 mM
L-glutamine, 100 U/ml penicillin, 100mg/ml streptomycin, and 9%
fetal bovine serum (FBS) (hereafter referred to as ‘‘complete DMEM’’).
Low-passage (5–10th) fibroblasts were used for transfection.
Transfection and expression of icIL-1ra type 1 in human dermal
fibroblasts
Fibroblasts were transfected using LipofectAMINE 2000 reagent
obtained from Invitrogen Life Technologies Inc. (Gaithersburg, MD)
following the manufacturer’s protocol. Briefly, 1 day prior to
transfection, 2 105 fibroblasts were seeded per well (in 500 ml) in
a 24-well plate. The cells were maintained in complete DMEM
without antibiotics. For transfection of each well, B1.0 mg of
plasmid DNA was taken up in 50 ml of OPTI-MEM with reduced
serum (Life Technologies Inc.). For each well of cells to be
transfected, 2ml of LipofectAMINE reagent was added to 50 ml of
OPTI-MEM and incubated at ambient temperature for 5 minutes.
Diluted plasmid DNA was then combined with the diluted
LipofectAMINE reagent and incubated at ambient temperature for
20 minutes to allow DNA–LipofectAMINE complexes to form. The
plasmid DNA–LipofectAMINE complex was then added to each well
and mixed gently by rocking the plates back and forth. The cells
were incubated at 371C for 4–6 hours. To each well, an additional
500ml of OPTI-MEM with reduced serum was added and the
incubation continued for another 48–72 hours. The medium was
then replaced with complete DMEM containing 600 mg/ml of
geneticin (Life Technologies Inc.). Cells were incubated for 5–7
days with removal of dead cells and replenishment with complete
medium containing 600 mg/ml geneticin. Several days later and after
3–4 subcultures, only cells resistant to geneticin (600 mg/ml) were
remaining. The stably transfected cells were tested for the expression
of icIL-1ra type 1 mRNA by real-time RT-PCR and for the expression
of icIL-1ra protein by ELISA. Aliquots of cells stably transfected with
icIL-1ra type 1 (HF-icIL-1ra) and of control cells (HF-Vector) were
preserved for future use by freezing in complete DMEM containing
10% DMSO.
Estimation of total icIL-1ra type 1 protein in transfected
fibroblasts
Total icIL-1ra type 1 was measured by ELISA (R&D Systems,
Minneapolis, MN). The transfected cells were harvested, washed
once in serum-free DMEM, counted manually in a hemocytometer,
and lysed by incubation for 30 minutes at 41C with 50 mM Tris, 0.1%
3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (Sig-
ma Aldrich Chemicals, St Louis, MO) and 0.1% Nonidet P-40 pH
7.5, containing protease inhibitors (25 mM benzamidine, 1 mM
phenylmethanesulfonyl fluoride, 10 mM N-ethylmaleimide, 1 mM
EDTA, 1.0 mg/ml leupeptin, 1.0mg/ml aprotinin, and 1.0 mg/ml
pepstatin). The cell lysates were cleared by centrifugation at
18,000 g for 30 minutes at 41C. Cleared lysates were stored at
801C until tested after adding 0.1 volumes of NaCl (to a final
concentration of 0.9%) to each sample. The concentration of total
icIL-1ra is expressed as ng/1 106 vector-transfected (HF-Vector) or
icIL-1ra-transfected (HF-icIL-1ra) cells.
Estimation of IL-1ra protein in culture supernatants of
transfected fibroblasts
Culture supernatants were collected from the transfected fibroblasts
to determine the levels of IL-1ra that was released into the culture
medium. IL-1ra protein was estimated by ELISA method as described
above using reagents obtained from R&D Systems.
Stimulation of cultured fibroblasts with IL-1b, TNF-a, and PMA
Transfected fibroblasts were continuously maintained in complete
DMEM containing 600 mg/ml geneticin. To study the effect of
hrIL-1b, hrTNF-a (R&D Systems), or PMA (Promega), fibroblasts were
harvested from confluent monolayers by trypsin treatment. Equal
numbers of fibroblasts/well were seeded in 12- or 24-well plates and
grown to confluence for 72 hours. One day prior to treatment with
hrIL-1b, hrTNF-a, or PMA, the initial growth medium was replaced
with complete DMEM containing 5% FBS. Separate plates were set
up for mRNA and protein analysis. Duplicate wells were set up for
each assay condition. Fibroblasts were then exposed to 1.0 ng/ml
hrIL-1b, 5 or 10 ng/ml hrTNF, or 10 ng/ml of PMA and were
harvested 12–16 hours later for mRNA analysis. One milliliter of Tri-
Reagent was added to each well to lyse the fibroblasts. The cell
lysates thus obtained were stored at801C until analyzed. For MMP-1
protein estimation, the fibroblasts set up as above were incubated for
48 hours with hrIL-1b (1.0 ng/ml) and hrTNF-a (5 ng/ml) after which
the cell culture supernatants were collected and stored at 801C
until tested.
Stimulation of normal human foreskin fibroblasts with TNF-a in
the presence of rhIL-1ra
Normal human fibroblasts (70–80%) maintained in DMEM containing
5% FBS in 24-well plates were exposed to varying concentrations
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(0, 25 pg/ml, 1.0 ng/ml, 10 ng/ml, 15 ng/ml, 50 ng/ml) of
rhIL-1ra (R&D Systems) 2 hours prior to the addition of 5 ng/ml
TNF-a. This was performed to determine whether extracellular IL-1ra
could simulate the effect of intracellular form of IL-1ra on TNF-
induced MMP expression. The supernatants from these cultures were
collected after 48 hours and were stored at 801C until tested for
collagenase.
Estimation of MMP-1 protein
MMP-1 protein secreted into the culture medium was measured by
ELISA, performed as previously described using the protein analysis
program of Stoscheck (1987). Rabbit anti-human MMP-1 antibody
was kindly provided by Dr George Stricklin, VAMC and Vanderbilt
University Medical College, Nashville, TN. Culture supernatants
were collected 48 hours after treatment with hrIL-1b and hrTNF-a
and cleared by centrifugation at 18,000 g for 30 minutes at 41C.
Cleared supernatants were treated with protease inhibitors (25 mM
benzamidine, 1 mM phenylmethanesulfonyl fluoride, 10 mM N-ethyl-
maleimide, 1 mM EDTA, 1.0 mg/ml leupeptin, 1.0 mg/ml aprotinin,
1.0 mg/ml pepstatin) and stored at 801C until tested.
Estimation of mRNA by real-time RT-PCR
Total cellular RNA was isolated from the cells using Tri-Reagent
(Sigma-Aldritch, St Louis, MO) followed by chloroform (Sigma-
Aldritch) extraction and isopropanol (Sigma-Aldritch) precipitation.
The total RNA was used for oligo(dT)-mediated reverse transcription
of mRNA species in each sample. Specific messages were amplified
and detected by real-time PCR performed using the SYBR Green
method (Applied Biosystems, Foster City, CA) using specific sets of
forward and reverse primers (Table 4) synthesized at Integrated DNA
Technologies Inc. (Coralville, IA). The reactions were performed
according to the manufacturer’s protocol. Each sample was assayed
in duplicate. The PCR product was detected by measuring the
increase in fluorescence caused by the binding of the SYBR Green
dye to double-stranded DNA. The specificity of the product was
confirmed by a specific melting/dissociation curve for each product.
The housekeeping gene glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as a control to normalize for the amount of RNA
present in various test samples. The relative value of specific mRNAs
in each sample was expressed as a reciprocal ratio of the Ct values of
each message to those of the corresponding GAPDH.
Assessment of myofibroblast phenotype
Myofibroblast phenotype was assessed by light microscopy, im-
munoperoxidase staining for a-SMA, estimation of mRNA levels of
a-SMA, and expression of PAI by SYBR Green staining of real-time
RT-PCR using specific primers listed in Table 4. For immunoperoxi-
dase staining, HF-Vector and HF-icIL-1ra fibroblasts were grown to
subconfluency in 48-well flat-bottom tissue culture plates.
As a control, human foreskin fibroblasts maintained in the
presence of rhTGF-b (10 ng/ml) for 2 weeks and plated similarly in
48-well plates were used. The medium was removed and cell layers
were incubated with Cytofix/Cytoperm for 20 minutes and then with
0.3% hydrogen peroxidase (Sigma-Aldritch) for 5 minutes. There-
after, cell layers were washed three times with PermWash (BD
Pharmingen, San Diego, CA) and cell monolayers were incubated
with PBS containing 2% BSA for 20 minutes and washed three times
with PermWash. A 1:25 dilution of Sigma’s mouse anti-human
a-SMA clone 1A 4 monoclonal antibody was added to the cell
monolayers for 30 minutes and washed three times with PermWash.
Cell monolayers were then incubated with biotinylated rat anti-
mouse IgG (Fab-specific) (Sigma-Aldritch) for 30 minutes and
washed three times with PermWash. Streptavidin–horseradish
peroxidase was then added to the cell layers for 10 minutes and
the cell layers were washed three times with PermWash. Substrate
AEC (BD Pharmingen) was added to the cell monolayers for
10 minutes and cell monolayers were washed with distilled water
and counterstained with 0.02% Coomassie blue (Sigma-Aldritch) for
20 minutes and finally washed three times with distilled water.
Treatment of transfected human dermal fibroblasts with
icIL-1ra type 1 antisense oligonucleotide
A phosphorothioate-derivatized antisense oligodeoxynucleotide
complimentary to 6 to þ 12 (50-CGTCTGTAAAGGCATGGG-30)
of the natural icIL-1ra type 1 was synthesized and reverse phase high
performance liquid chromatography purified by Integrated DNA
Technologies Inc. An antisense oligonucleotide with a scrambled
sequence was prepared by a similar method and used as a control.
Fibroblasts overexpressing icIL-1ra type 1 were transfected with 50,
100, and 300 mM of icIL-1ra type 1 antisense oligonucleotide
(24 hours prior to stimulation with 1.0 ng/ml of hrIL-1b) using the
LipofectAMINE protocol as described above. Fibroblasts cultured
with PBS or the transfecting agent alone served as additional
Table 4. Primer sequences (50–30) used in real-time RT-PCR
Target Sense (50–30) Antisense (50–30)
GAPDH GCA GGG GGG AGC CAA AAG GG TGC CAG CCC CAG CGT CAA AG
icIL-1ra type 1 CCA CCA TGG CTT TAG AGA CCA TC CTA CTC GTC CTC CTG GAA GTA
sIL-1ra GAA TGG AAA TCT GCA GAG GCC TCC GC GTA CTA CTC GTC CTC CTG G
MMP-1 ACC TGA AGA ATG ATG GGA GGC AAG T CAT CAA AAT GAG CAT CTC CTC CAA TAC CT
TIMP-1 AAC CCA CCA TGG CCC CCT TTG AG GTT CCA CTC CGG GCA GGA TTC AGG
a-SMA GTC CCC ATC TAT GAG GGC TAT GCA TTT GCG GTG GAC AAT GGA
PAI AAG GAC CGC AAC GTG GTT TTC TCA TGA AGA AGT GGG GCA TGA AGC C
Collagen I (a2) CAG ATA CTT GAA TGT TGA TGG CTG CTT GCC CAA GAA ACA AAG C
The oligonucleotides were synthesized and desalted at Integrated DNA Technology Inc., IA.
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controls. The fibroblasts were harvested for RNA extraction
12–18 hours after stimulation.
Statistical analysis
Student’s t-test was performed using Sigmastat 3.0 program (SPSS
Inc., Chicago, IL) to compare the two groups (fibroblasts transfected
with vector alone and fibroblasts transfected with vector encoding
icIL-1ra), both groups having subjected to the same treatment.
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